• Quadria Capital is partially exiting its investment in Nephrocare Health Services Ltd, the operator of NephroPlus dialysis centers, through the company's upcoming IPO. This partial exit is expected to yield Quadria Capital strong returns, with estimated annualised returns of 47-48% and a multiple on invested capital of 1.87 times.
• NephroPlus, a leading dialysis chain in India, is launching its IPO with a price band of Rs 438-460 per share, aiming for a post-IPO valuation of approximately Rs 4,615 crore ($510 million). The IPO includes both a fresh issue of capital and an offer for sale by existing shareholders.
• Quadria Capital invested approximately Rs 846 crore in May 2024 to acquire a significant minority stake in NephroPlus, which currently stands at 36.27%. The firm plans to sell shares worth Rs 132.9 crore at the upper end of the price band.
• Other investors like IFC and Investcorp are also participating in the offer for sale, with IFC expecting substantial gains and an IRR of 25-26% on its investment. Bessemer Venture Partners, holding a 9.9% stake, is not selling any shares in the IPO.

Roshan Abraham

Healthcare-focused private equity firm Quadria Capital is set to score strong returns on its investment by partially .........

Quadria Capital scoring spectacular returns from swift exit move

Markets

Private Equity

Healthcare

Healthcare-focused private equity firm Quadria Capital is set to score strong returns on its investment by partially exiting a dialysis chain operator that...

Quadria Capital

Investcorp

Bessemer Venture Partners

NephroPlus

VC_Desk_Story_Masthead

VC_Desk_Story_A_300x250

VC_Desk_Story_B_300x250

VC_Desk_Story_C_300x250

VC_Desk_Story_D_300x250

VC_Desk_Story_E_300x250

VC_Desk_Story_A_Skyscraper

VC_Desk_Story_B_Skyscraper

VC_Desk_Story_Inline_A_300x250

VC_Desk_Story_Inline_B_300x250

VC_Desk_Story_Inline_C_300x250

VC_Desk_Story_Inline_D_300x250

VC_Desk_Story_Inline_E_300x250

VC_Desk_Story_Footer

Corona Remedies Ltd made a spectacular stock market debut on Monday with shares of the drugmaker that counts private ......

ChrysCap-backed Corona Remedies nears $1 bn valuation after blockbuster debut

Bengaluru-based NU Hospitals Pvt Ltd is in the final stages of closing a funding round that has been in the ......

NU Hospitals in final lap of closing funding round

Baby Memorial Hospital, a multispecialty hospital backed by private equity major KKR & Co, is set to acquire a south ......

KKR set to acquire another South India hospital operator

Fireside Ventures-backed at-home diagnostics firm Inito has raised fresh capital to expand its offerings beyond ......

Fireside Ventures-backed healthtech firm Inito bags $29 mn in Series B

Private equity firm Vixar, which was earlier known as Arpwood Partners and rebranded this year, has acquired a majority ......

PE firm Vixar picks up majority stake in diagnostics firm

Consumer

Infrastructure

Private equity firm KKR, Singapore state investment firm Temasek, venture capital firm Aarin Capital and two other PE ......

KKR, Temasek, three other PE/VC firms move closer to harvesting India bets

Medway Hospitals, a South India-based chain of multi-speciality hospitals, is considering its maiden institutional ......

Quadria Capital scoring spectacular returns from swift exit move

New to VCCircle.com?

Related Articles

Healthcare

ChrysCap-backed Corona Remedies nears $1 bn valuation after blockbuster debut

Healthcare

NU Hospitals in final lap of closing funding round

Healthcare

KKR set to acquire another South India hospital operator

Healthcare

Fireside Ventures-backed healthtech firm Inito bags $29 mn in Series B

Healthcare

PE firm Vixar picks up majority stake in diagnostics firm

Consumer

KKR, Temasek, three other PE/VC firms move closer to harvesting India bets

Healthcare

South India-based Medway Hospitals plans first PE round, hires banker

Google News